Natco Pharma partner Viatris to launch first generic version of Nexavar tablets in US
Sorafenib is prescribed for treatment of unresectable Hepatocellular Carcinoma (HCC), advanced Renal Cell Carcinoma (RCC) and Differentiated Thyroid Carcinoma (DTC).
Hyderabad: Drugmaker, Natco Pharma Limited, has recently announced the launch of the first generic version of Nexavar (Sorafenib) Tablets in 200 mg strength today in the U.S. market.
The product will be launched by NATCO's commercial partner Viatris, a global pharmaceutical company.
Sorafenib is prescribed for treatment of unresectable Hepatocellular Carcinoma (HCC), advanced Renal Cell Carcinoma (RCC) and Differentiated Thyroid Carcinoma (DTC).
Read also: NATCO Announces Launch of the First Generic Version of Revlimid, in the U.S. market
Nexavar registered sales of USD 69.7 million for the year ending December 2021 as per industry sales data.
Nexavar is a registered trademark of Bayer Healthcare Pharmaceuticals Inc. All brand names and trademarks are the property of their respective owners.
Read also: Natco Pharma gets CDSCO nod to manufacture, market anti neoplastic drug Idelalisib
Natco Pharma Limited was incorporated in Hyderabad in the year 1981 with an initial investment of INR 3.3 million.
The company has seven manufacturing facilities spread across India with modern research laboratories, capabilities in New Drug Development, etc
